Berberine (CAS 2086-83-1): An AMPK Activator for Metabolic and Inflammation Research

Executive Summary: Berberine (CAS 2086-83-1) is an isoquinoline alkaloid with a molecular weight of 336.36 and formula C₂₀H₁₈NO₄ [ApexBio]. It demonstrates potent activation of AMP-activated protein kinase (AMPK), leading to modulation of glucose and lipid metabolism in human and animal models (Li et al., 2025). In hepatoma cell lines, it upregulates low-density lipoprotein receptor (LDLR) mRNA and protein in a dose-dependent manner, with maximal effect at 15 μg/mL. Oral administration in hyperlipidemic hamsters at 50–100 mg/kg/day for 10 days significantly reduces serum cholesterol and LDL cholesterol, correlating with increased hepatic LDLR expression. Berberine also exhibits robust anti-inflammatory and antimicrobial activities, making it a versatile tool for preclinical metabolic disease and inflammation research [Related: Amyloid Peptide].

Biological Rationale

Berberine is primarily extracted from Cortex Phellodendri Chinensis and belongs to the class of isoquinoline alkaloids [ApexBio]. Its primary research applications include metabolic disease models (diabetes, obesity, hyperlipidemia) and cardiovascular disease studies. The rationale for its use centers on its ability to activate AMPK, a master regulator of energy homeostasis, and to modulate metabolic and inflammatory signaling pathways. AMPK activation leads to enhanced glucose uptake, fatty acid oxidation, and inhibition of lipid synthesis (Li et al., 2025). Berberine’s anti-inflammatory properties are increasingly relevant as chronic low-grade inflammation is a hallmark of metabolic disorders. Its capacity to upregulate hepatic LDLR further supports its utility in lipid modulation and cardiovascular research [Compare: GW2580.com].

Mechanism of Action of Berberine (CAS 2086-83-1)

Berberine acts mainly through direct activation of AMP-activated protein kinase (AMPK) in multiple tissues, including liver, adipose, and muscle. AMPK activation by berberine increases cellular energy expenditure and enhances glucose transporter 4 (GLUT4) translocation in muscle cells. In hepatocytes, berberine upregulates low-density lipoprotein receptor (LDLR) gene and protein expression, promoting LDL cholesterol clearance. In HepG2 and Bel-7402 cell lines, maximal LDLR upregulation occurs at 15 μg/mL, measured after 24 hours of exposure. Berberine also inhibits pro-inflammatory signaling via downregulation of NLRP3 inflammasome activation, as observed in models of acute kidney injury, thereby reducing cytokine release (e.g., IL-1β, IL-18) (Li et al., 2025). Additionally, berberine exhibits antimicrobial activity by disrupting microbial membrane integrity and inhibiting nucleic acid synthesis.

Evidence & Benchmarks

• Berberine upregulates LDLR mRNA and protein in human hepatoma cell lines (HepG2, Bel-7402) in a dose-dependent manner, with maximum effect at 15 μg/mL over 24 h (https://www.apexbt.com/berberine.html).
• Oral berberine at 50–100 mg/kg/day for 10 days significantly reduces serum total cholesterol and LDL cholesterol in hyperlipidemic female golden hamsters (https://www.apexbt.com/berberine.html).
• Activation of AMPK by berberine leads to improved glucose uptake and lipid oxidation in metabolic disease models (https://doi.org/10.1038/s41392-025-02194-y; see Fig. 2).
• In acute kidney injury models, berberine reduces NLRP3 inflammasome activation and cytokine release (Li et al. 2025, https://doi.org/10.1038/s41392-025-02194-y).
• Berberine is insoluble in water and ethanol but dissolves at ≥14.95 mg/mL in DMSO; solubility improves with warming to 37°C or ultrasonic agitation (https://www.apexbt.com/berberine.html).

Applications, Limits & Misconceptions

Berberine is applied in cellular, animal, and molecular models of metabolic disease and inflammation. It is used to upregulate LDLR, modulate AMPK pathways, and attenuate NLRP3-mediated inflammatory responses. Its role in diabetes, obesity, hyperlipidemia, and cardiovascular disease research is well-documented. Emerging uses include inflammasome and acute kidney injury models where modulation of innate immunity is crucial [Contrast: Agarose GPG LE]. This article extends existing reviews by focusing on protocol-level solubility, storage, and dosing considerations for high reproducibility.

Common Pitfalls or Misconceptions

• Berberine is not water- or ethanol-soluble; DMSO is required for stock solutions.
• Long-term storage of berberine solutions at room temperature leads to degradation; stocks should be kept at -20°C and used promptly.
• Oral doses above 100 mg/kg/day in animal models may induce gastrointestinal side effects; always titrate based on pilot data.
• Not all anti-inflammatory effects are mediated by AMPK; inflammasome pathways may be independently modulated.
• Berberine’s half-life and bioavailability are low; results in cell models may not directly translate to in vivo dosing without pharmacokinetic adjustment.

Workflow Integration & Parameters

• Solubility: Dissolve berberine at ≥14.95 mg/mL in DMSO. Warming the mixture to 37°C or using ultrasonic agitation ensures complete dissolution [ApexBio].
• Storage: Store solid berberine at -20°C, protected from moisture and heat. Prepare fresh solutions for each experiment and avoid repeated freeze-thaw cycles.
• Cellular Models: For LDLR upregulation, use HepG2 or Bel-7402 cells and treat with 1–15 μg/mL berberine for 24 h.
• Animal Models: In hyperlipidemic hamsters, administer 50 or 100 mg/kg/day orally for 10 days; monitor serum cholesterol and hepatic LDLR expression.
• Inflammasome Studies: Berberine can be used to attenuate NLRP3-mediated pyroptosis; reference standardized protocols from acute kidney injury research (Li et al., 2025).
• For further methodological guidance and comparison to other metabolic modulators, see Berberine: AMPK Activator for Metabolic & Inflammation Research, which this article updates with detailed dosing and solubility data.

Conclusion & Outlook

Berberine (CAS 2086-83-1) is a rigorously validated tool for modulating AMPK activity, LDLR expression, and inflammatory signaling in metabolic and cardiovascular disease models. Its unique solubility and dosing characteristics enable precise experimental design. Ongoing research is clarifying its roles in inflammasome regulation and acute organ injury, expanding its utility beyond traditional metabolic pathways. For ready-to-use product details and protocols, see the N1368 kit at ApexBio.